$IMNM
Immunome Inc.

2024 Q1 Form 10-K Financial Statement

#000155837024004247 Filed on March 28, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $1.029M $3.826M $14.02M
YoY Change -56.47%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.005M $8.150M $19.82M
YoY Change 102.67% 128.04% 43.71%
% of Gross Profit
Research & Development $15.37M $9.527M $22.93M
YoY Change 292.77% 126.13% -1.49%
% of Gross Profit
Depreciation & Amortization $157.0K $147.0K $457.0K
YoY Change 67.02% 54.74% 14.25%
% of Gross Profit
Operating Expenses $133.3M $17.68M $42.75M
YoY Change 1850.67% 127.01% 15.84%
Operating Profit -$132.3M -$109.5M
YoY Change 2859.05% 196.82%
Interest Expense $2.807M $2.019M $2.724M
YoY Change 1296.52% 201800.0% 54380.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$129.5M -$92.63M -$106.8M
YoY Change 2932.6% 1089.75% 189.48%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$129.5M -$92.63M -$106.8M
YoY Change 2911.44% 1089.75% 189.45%
Net Earnings / Revenue -12584.26% -2421.17% -761.92%
Basic Earnings Per Share -$2.51 -$5.38
Diluted Earnings Per Share -$2.51 -$2.17 -$5.38
COMMON SHARES
Basic Shares Outstanding 59.69M 42.73M 19.84M
Diluted Shares Outstanding 51.54M 19.84M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $309.7M $138.1M $138.1M
YoY Change 597.2% 579.73% 579.73%
Cash & Equivalents $269.7M $98.68M
Short-Term Investments $40.00M $39.46M $39.46M
Other Short-Term Assets $3.620M $6.561M $6.561M
YoY Change 180.4% 182.07% 343.61%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $313.3M $144.7M $144.7M
YoY Change 573.3% 538.89% 538.89%
LONG-TERM ASSETS
Property, Plant & Equipment $4.302M $3.637M $3.637M
YoY Change 369.65% 434.07% 276.89%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $568.0K $200.0K $200.0K
YoY Change 31.48% -53.7% -53.7%
Total Long-Term Assets $6.428M $3.837M $3.837M
YoY Change 307.35% 174.66% 174.66%
TOTAL ASSETS
Total Short-Term Assets $313.3M $144.7M $144.7M
Total Long-Term Assets $6.428M $3.837M $3.837M
Total Assets $319.8M $148.5M $148.5M
YoY Change 564.58% 517.73% 517.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.179M $3.311M $3.311M
YoY Change 116.89% 37.96% 37.96%
Accrued Expenses $10.79M $8.025M $8.025M
YoY Change 226.35% 62.75% 62.75%
Deferred Revenue $12.75M $10.49M
YoY Change -30.03%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $30.77M $21.83M $21.83M
YoY Change 23.91% 197.76% 197.76%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $3.414M $6.829M $6.829M
YoY Change -63.76% 10914.52% 10914.52%
Total Long-Term Liabilities $3.414M $6.829M $6.829M
YoY Change -63.76% 10914.52% 10914.52%
TOTAL LIABILITIES
Total Short-Term Liabilities $30.77M $21.83M $21.83M
Total Long-Term Liabilities $3.414M $6.829M $6.829M
Total Liabilities $34.18M $28.66M $28.66M
YoY Change -0.2% 287.64% 287.64%
SHAREHOLDERS EQUITY
Retained Earnings -$352.3M -$222.8M
YoY Change 192.85% 92.07%
Common Stock $6.000K $4.000K
YoY Change 500.0% 300.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $285.6M $119.9M $119.9M
YoY Change
Total Liabilities & Shareholders Equity $319.8M $148.5M $148.5M
YoY Change 564.58% 517.73% 517.73%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$129.5M -$92.63M -$106.8M
YoY Change 2911.44% 1089.75% 189.45%
Depreciation, Depletion And Amortization $157.0K $147.0K $457.0K
YoY Change 67.02% 54.74% 14.25%
Cash From Operating Activities -$11.17M -$17.46M -$7.568M
YoY Change -146.21% 161.23% -73.62%
INVESTING ACTIVITIES
Capital Expenditures $2.164M $351.0K $831.0K
YoY Change 1941.51% 387.5% 235.08%
Acquisitions
YoY Change
Other Investing Activities -$29.65M -$29.65M
YoY Change
Cash From Investing Activities -$37.23M -$30.00M -$30.48M
YoY Change 35023.58% 41572.22% 12191.94%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $405.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 219.4M 55.50M 116.4M
YoY Change 645326.47% 363675.0%
NET CHANGE
Cash From Operating Activities -11.17M -17.46M -7.568M
Cash From Investing Activities -37.23M -30.00M -30.48M
Cash From Financing Activities 219.4M 55.50M 116.4M
Net Change In Cash 171.0M 8.036M 78.36M
YoY Change 609.7% -218.96% -371.07%
FREE CASH FLOW
Cash From Operating Activities -$11.17M -$17.46M -$7.568M
Capital Expenditures $2.164M $351.0K $831.0K
Free Cash Flow -$13.33M -$17.81M -$8.399M
YoY Change -155.4% 163.64% -70.98%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001472012
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43251778
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12128843
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-39580
CY2023 dei Entity Registrant Name
EntityRegistrantName
IMMUNOME, INC.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
77-0694340
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
18702 N. Creek Parkway
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Bothell
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
WA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
98011
CY2023 dei City Area Code
CityAreaCode
610
CY2023 dei Local Phone Number
LocalPhoneNumber
321-3700
CY2023 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 Par Value
CY2023 dei Trading Symbol
TradingSymbol
IMNM
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
75500000
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
59694243
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
70000
CY2023 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
371000
CY2023 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
87161000
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023 dei Auditor Firm
AuditorFirmId
42
CY2023 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2023 dei Auditor Location
AuditorLocation
Philadelphia, Pennsylvania
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
98679000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20323000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
39463000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6561000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2326000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
144703000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
22649000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2073000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
681000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1564000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
284000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
100000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
100000
CY2022Q4 us-gaap Deferred Costs
DeferredCosts
332000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
100000
CY2023Q4 us-gaap Assets
Assets
148540000
CY2022Q4 us-gaap Assets
Assets
24046000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3311000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2400000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
8025000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
4931000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
10493000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
21829000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7331000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
5489000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1340000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
62000
CY2023Q4 us-gaap Liabilities
Liabilities
28658000
CY2022Q4 us-gaap Liabilities
Liabilities
7393000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43251778
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12128843
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-106806000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
119882000
CY2023 us-gaap Profit Loss
ProfitLoss
-106806000
CY2022 us-gaap Profit Loss
ProfitLoss
-36896000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
342663000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
132653000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
22000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-222807000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-116001000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
119882000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
16653000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
148540000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
24046000
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14018000
CY2023 imnm In Process Research And Development Expense
InProcessResearchAndDevelopmentExpense
80802000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23089000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23272000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19657000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13629000
CY2023 us-gaap Operating Expenses
OperatingExpenses
123548000
CY2022 us-gaap Operating Expenses
OperatingExpenses
36901000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-109530000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-36901000
CY2023 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
2724000
CY2022 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
5000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-106806000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-36896000
CY2022 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
622000
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-106806000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-37518000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.38
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.38
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.09
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.09
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19843651
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19843651
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12126573
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12126573
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-106806000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-37518000
CY2023 us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
22000
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-106784000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-37518000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
48185000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5332000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
32000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-36896000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
16653000
CY2023 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
22000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6153000
CY2023 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
221000
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
457000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
422000
CY2023 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
271000
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
209000
CY2023 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
512000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
6223000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
5332000
CY2023 imnm In Process Research And Development Expense
InProcessResearchAndDevelopmentExpense
80802000
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4144000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-5071000
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-608000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-677000
CY2023 imnm Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
614000
CY2022 imnm Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
-1922000
CY2023 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
15982000
CY2023 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
153000
CY2022 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-229000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7568000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28690000
CY2023 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
38929000
CY2023 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
9276000
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
831000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
248000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-30484000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-248000
CY2023 imnm Payment Of Offering Costs
PaymentOfOfferingCosts
8997000
CY2023 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
125000000
CY2023 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
371000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
32000
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
34000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
116408000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
32000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
78356000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-28906000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20423000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
49329000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
98779000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20423000
CY2022 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
492000
CY2023 us-gaap Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Shares Issued1
NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1
87161000
CY2023 imnm Remeasurement Of Operating Lease Right Of Use Asset And Lease Liability Due To Lease
RemeasurementOfOperatingLeaseRightOfUseAssetAndLeaseLiabilityDueToLease
226000
CY2023 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1325000
CY2023 us-gaap Stock Issued1
StockIssued1
221000
CY2023 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
372000
CY2023Q4 imnm Number Of Clinical Assets
NumberOfClinicalAssets
1
CY2023Q4 imnm Number Of Preclinical Assets
NumberOfPreclinicalAssets
3
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-106800000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-36900000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-222800000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
98679000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the expected volatility used to estimate fair value of stock options, accrued research and development expenses, the fair value of acquired in-process research and development assets, and the estimated costs which drive the revenue recognition for the Collaboration Agreement with AbbVie. Estimates and assumptions are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from these estimates.</p>
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
100000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
100000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20323000
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
100000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
100000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
98779000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20423000
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of credit risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents and marketable securities. The Company maintains deposits in a financial institution in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company’s deposits are held at a financial institution that management believes to be of high credit quality, and the Company has not experienced any losses on these deposits. Management also believes that the Company is not exposed to significant credit risk as it relates to marketable securities because the Company only invests in U.S government securities.</p>
CY2022 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2023 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2022 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
300000
CY2023 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8478291
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023 imnm Debt Securities Available For Sale Contractual Maturity Term
DebtSecuritiesAvailableForSaleContractualMaturityTerm
P6M
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3822517
CY2023Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
4009000
CY2023Q4 imnm Prepaid Subscriptions Prepaid Service Contracts And Short Term Deposits
PrepaidSubscriptionsPrepaidServiceContractsAndShortTermDeposits
718000
CY2022Q4 imnm Prepaid Subscriptions Prepaid Service Contracts And Short Term Deposits
PrepaidSubscriptionsPrepaidServiceContractsAndShortTermDeposits
876000
CY2022Q4 imnm Employee Retention Credit Receivable
EmployeeRetentionCreditReceivable
847000
CY2023Q4 imnm Research And Development Expense Advance Payments
ResearchAndDevelopmentExpenseAdvancePayments
336000
CY2022Q4 imnm Research And Development Expense Advance Payments
ResearchAndDevelopmentExpenseAdvancePayments
445000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
950000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
158000
CY2023Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
289000
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
259000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6561000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2326000
CY2023Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
5981000
CY2022Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
4132000
CY2023Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
3908000
CY2022Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
3451000
CY2023Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
2073000
CY2022Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
681000
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
500000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
400000
CY2023Q4 imnm Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
1680000
CY2022Q4 imnm Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
2261000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2734000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1874000
CY2023Q4 imnm Severance Accruals Current
SeveranceAccrualsCurrent
1436000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1670000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
481000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
310000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
229000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
195000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
86000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
8025000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
4931000
CY2022 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
200000
CY2023 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
200000
CY2023Q4 imnm Collaborative Arrangements Product Development And Regulatory Approval Milestone Payments Payable
CollaborativeArrangementsProductDevelopmentAndRegulatoryApprovalMilestonePaymentsPayable
2900000
CY2023Q4 imnm Collaborative Arrangements Commercial Milestone Payments Payable
CollaborativeArrangementsCommercialMilestonePaymentsPayable
2800000
CY2022 imnm Collaborative Agreement Milestone Payments Made
CollaborativeAgreementMilestonePaymentsMade
100000
CY2023 imnm Collaborative Agreement Milestone Payments Made
CollaborativeAgreementMilestonePaymentsMade
0
CY2023 imnm Common Stock Voting Right
CommonStockVotingRight
1
CY2022Q3 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
600000
CY2022Q3 imnm Deemed Dividends Stockholder S Equity Statement Impact
DeemedDividendsStockholderSEquityStatementImpact
0
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6223000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5332000
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
22800000
CY2023 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y10M24D
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.921
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.856
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.046
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.027
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y7M6D
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2023Q4 imnm Fair Value Of Common Stock
FairValueOfCommonStock
7.92
CY2022Q4 imnm Fair Value Of Common Stock
FairValueOfCommonStock
3.63
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2519405
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.60
CY2023 imnm Share Based Compensation Arrangement By Share Based Payment Award Options Replacement Options Issued At Asset Acquisition
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsReplacementOptionsIssuedAtAssetAcquisition
2472563
CY2023 imnm Share Based Compensation Arrangements By Share Based Payment Award Options Weighted Average Exercise Price Of Replacement Options Issued At Acquisition
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceOfReplacementOptionsIssuedAtAcquisition
1.29
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4007552
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.42
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
314319
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.67
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
55670
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
16.59
CY2023 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
651240
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.57
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7978291
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.15
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y7M13D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3151799
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.86
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y6M14D
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.09
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.65
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
5900000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
200000
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
21900000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
45400000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
700000
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.013
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.043
CY2022 imnm Effective Income Tax Rate Reconciliation State Tax Legislation Net Of Federal Benefit Percent
EffectiveIncomeTaxRateReconciliationStateTaxLegislationNetOfFederalBenefitPercent
-0.071
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.007
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.019
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
-0.009
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
-0.002
CY2023 imnm Effective Income Tax Rate Reconciliation Nondeductible Expense Write Off Of In Process Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseWriteOffOfInProcessResearchAndDevelopment
-0.159
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.036
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.199
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
22784000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
20523000
CY2023Q4 imnm Deferred Tax Assets Research And Development Intangibles
DeferredTaxAssetsResearchAndDevelopmentIntangibles
10135000
CY2022Q4 imnm Deferred Tax Assets Research And Development Intangibles
DeferredTaxAssetsResearchAndDevelopmentIntangibles
4839000
CY2023Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
3782000
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
2878000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2533000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2016000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses
546000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses
383000
CY2023Q4 imnm Deferred Tax Asset Lease Liabilities
DeferredTaxAssetLeaseLiabilities
350000
CY2023Q4 imnm Deferred Tax Assets Amortization
DeferredTaxAssetsAmortization
75000
CY2022Q4 imnm Deferred Tax Assets Amortization
DeferredTaxAssetsAmortization
1000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
40205000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
30640000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
39827000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
30609000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
378000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
31000
CY2023Q4 imnm Deferred Tax Liabilities Depreciation
DeferredTaxLiabilitiesDepreciation
46000
CY2022Q4 imnm Deferred Tax Liabilities Depreciation
DeferredTaxLiabilitiesDepreciation
31000
CY2023Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
332000
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
378000
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
31000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
9200000
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
7400000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
92600000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
84300000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration
DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
75600000
CY2023 imnm Net Operating Loss Carryforwards Offset Percent Of Taxable Income Maximum Percentage
NetOperatingLossCarryforwardsOffsetPercentOfTaxableIncomeMaximumPercentage
0.80
CY2023 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
200000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
37000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
37000

Files In Submission

Name View Source Status
0001558370-24-004247-index-headers.html Edgar Link pending
0001558370-24-004247-index.html Edgar Link pending
0001558370-24-004247.txt Edgar Link pending
0001558370-24-004247-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20231231.xsd Edgar Link pending
tmb-20231231x10k.htm Edgar Link pending
tmb-20231231x10k001.jpg Edgar Link pending
tmb-20231231x10k002.jpg Edgar Link pending
tmb-20231231x10k003.jpg Edgar Link pending
tmb-20231231x10k004.jpg Edgar Link pending
tmb-20231231x10k005.jpg Edgar Link pending
tmb-20231231x10k006.jpg Edgar Link pending
tmb-20231231x10k007.jpg Edgar Link pending
tmb-20231231x10k008.jpg Edgar Link pending
tmb-20231231x10k009.jpg Edgar Link pending
tmb-20231231x10k010.jpg Edgar Link pending
tmb-20231231x10k011.jpg Edgar Link pending
tmb-20231231x10k012.jpg Edgar Link pending
tmb-20231231x10k013.jpg Edgar Link pending
tmb-20231231x10k014.jpg Edgar Link pending
tmb-20231231xex10d16.htm Edgar Link pending
tmb-20231231xex10d17.htm Edgar Link pending
tmb-20231231xex10d18.htm Edgar Link pending
tmb-20231231xex10d19.htm Edgar Link pending
tmb-20231231xex10d20.htm Edgar Link pending
tmb-20231231xex10d21.htm Edgar Link pending
tmb-20231231xex10d22.htm Edgar Link pending
tmb-20231231xex10d23.htm Edgar Link pending
tmb-20231231xex10d30.htm Edgar Link pending
tmb-20231231xex10d32.htm Edgar Link pending
tmb-20231231xex10d32001.jpg Edgar Link pending
tmb-20231231xex10d33.htm Edgar Link pending
tmb-20231231xex10d34.htm Edgar Link pending
tmb-20231231xex10d34001.jpg Edgar Link pending
tmb-20231231xex10d37.htm Edgar Link pending
tmb-20231231xex10d38.htm Edgar Link pending
tmb-20231231xex10d38002.jpg Edgar Link pending
tmb-20231231xex21d1.htm Edgar Link pending
tmb-20231231xex23d1.htm Edgar Link pending
tmb-20231231xex31d1.htm Edgar Link pending
tmb-20231231xex31d2.htm Edgar Link pending
tmb-20231231xex32d1.htm Edgar Link pending
tmb-20231231xex32d2.htm Edgar Link pending
tmb-20231231xex97.htm Edgar Link pending
tmb-20231231_def.xml Edgar Link unprocessable
tmb-20231231_lab.xml Edgar Link unprocessable
tmb-20231231_pre.xml Edgar Link unprocessable
tmb-20231231_cal.xml Edgar Link unprocessable
tmb-20231231x10k_htm.xml Edgar Link completed